Pharmacokinetics of oral ivabradine in healthy cats

Journal of Veterinary Pharmacology and Therapeutics

Volumn 34, Issue 5, 2011, Pages 469-475

  Riesen, S C ^a   Ni, W ^a   Carnes, C A ^a   Lindsey, K J ^a   Phelps, M A ^a   Schober, Karsten E ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; IVABRADINE; S 18982; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CAT; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG ISOLATION; DRUG TOLERABILITY; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VALIDATION STUDY;

ADMINISTRATION, ORAL; ANIMALS; BENZAZEPINES; CARDIOVASCULAR AGENTS; CAT DISEASES; CATS; CHROMATOGRAPHY, LIQUID; FEMALE; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

EID: 80052666885     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2010.01253.x     Document Type: Article

References (18)

1. Bois, P., Bescond, J., Renaudon, B. & Lenfant, J. (1996) Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. British Journal of pharmacology, 118, 1051-1057.
2. f channel inhibitor, on heart rate in healthy cats. Journal of Veterinary Internal Medicine, 24, 695.
3. f) to generation of spontaneous activity in rabbit sino-atrial node myocytes. The Journal of Physiology, 434, 23-40.
4. f current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs, 64, 1757-1765.
5. Duffull, S.B. & Chabaud, S. (2000) A pharmacokinetic simulation model for ivabradine in healthy volunteers. European Journal of Pharmaceutical Sciences, 10, 285-294.
6. EPAR. (2005) Ivabradine European Public Assessment Report. Revision 5.
7. Evans, N.D., Godfrey, K.R., Chapman, M.J., Chappell, M.J., Aarons, L. & Duffull, S.B. (2001) An identifiability analysis of a parent-metabolite pharmacokinetic model for ivabradine. Journal of Pharmacokinetics and Pharmacodynamics, 28, 93-105.
8. Fink-Gremmels, J. (2008) Implications of hepatic cytochrome P450-related biotransformation processes in veterinary sciences. European Journal of Pharmacology, 585, 502-509.
9. François-Bouchard, M., Simonin, G., Bossant, M.-J. & Boursier-Neyret, C. (2000) Simultaneous determination of ivabradine and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography B, 745, 261-269.
10. Hirsch, S. & Dilger, C. (2005) Validation of an Analytical Method for the Measurement of S16257 and and its Metabolite S18982 in Mouse, Rat, Rabbit, Dog and Pig Plasma Samples by Liqid Chromatography with Tandem Mass Spectrometry Detection. Validation Report AAI No. OA128.
11. Klippert, P., Jeanniot, J.-P., Polvé, S., Lefèvre, C. & Merdjan, H. (1998) Determination of ivabradine and its N-demethylated metabolite in human plasma and urine, and in rat and dog plasma by validated high-performance liquid chromatographic method with fluorescence detection. Journal of Chromatography B, 719, 125-133.
12. MacGregor, J.M., Rush, J.E., Rozanski, E.A., Boothe, D.M., Belmonte, A.A. & Freeman, L.M. (2008) Comparison of pharmacodynamic variables following oral versus transdermal administration of atenolol to healthy cats. American Journal of Veterninary Research, 69, 39-44.
13. Macy, D.W. (1994) Pharmacologic considerations in the cat. Feline Practice, 22, 14-18.
14. Portolés, A., Calvo, A., Terleira, A., Laredo, L., Resplandy, G., Gorostiaga, C. & Moreno, A. (2006) Lack of Pharmacokinetic interaction between ompeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial. Journal of Clinical Pharmacology, 46, 1195-1203.
15. Quiñones, M., Dyer, D.C., Ware, W.A. & Mehvar, R. (1996) Pharmacokinetics of atenolol in clinically normal cats. American Journal of Veterninary Research, 57, 1050-1053.
16. Ragueneau, I., Laveille, C., Jochemsen, R., Resplandy, G., Funck-Brentano, C. & Jaillon, P. (1998) Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clinical Pharmacology & Therapeutics, 64, 192-203.
17. Riesen, S.C., Schober, K.E., Smith, D.N., Otoni, C.C. & Bonagura, J.D. (2010) Effects of ivabradine on invasive indices of LV function in anesthetized cats with hypertrophic cardiomyopathy. Journal of Veterinary Internal Medicine, 24, 692-693.
18. Shah, S.S., Sanda, S., Regmi, N.L., Sasaki, K. & Shimoda, M. (2007) Characterization of cytochrome P450-mediated drug metabolism in cats. Journal of Veterinary Pharmacology & Therapeutics, 30, 422-428.